Patient characteristics and outcomes according to IDH1/2 mutational status
| Characteristics . | mutIDH1 (n = 12), n (%) . | wtIDH1 (n = 113), n (%) . | P value . | mutIDH2 (n = 26), n (%) . | wtIDH2 (n = 99), n (%) . | P value . | mutIDH (n = 38), n (%) . | wtIDH (n = 89), n (%) . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| Age, y, median (range) | 74.5 (53-92) | 71 (27.8-95) | NS | 72 (47-87) | 71 (28-95) | NS | 73 (47-92) | 70 (28-95) | NS |
| Sex (man/woman) | 9/3 (75/25) | 85/28 (75.2/24.8) | NS | 22/4 (84.6/15.4) | 72/27 (72.7/27.3) | NS | 31/7 (81.6/18.4) | 65/24 (73/27) | NS |
| Leukocytes, ×109/L, median (range) | 4.9 (3.3-27.6) | 8.3 (2.4-93.7) | NS | 7.2 (3.1-54.3) | 8.3 (2.4-94) | NS | 7.1 (3.1-54) | 9.1 (2.4-94) | NS |
| Neutrophils, median (range) | 1.97 (0.5-14.8) | 3.9 (0.4-41) | NS | 3.4 (0.4-40.3) | 3.9 (0.4-41) | NS | 3.3 (0.4-40.3) | 4.2 (0.4-41) | NS |
| Monocytes, median (range) | 1 (0.7-8.5) | 1.8 (0.5-33.7) | NS | 1.6 (0.5-12.2) | 1.8 (0.5-33.8) | NS | 1.4 (0.5-12.2) | 1.9 (0.5-33.7) | NS |
| % monocytes, median (range) | 23.5 (10.6-60.9) | 21.2 (10-62.4) | NS | 20 (10-62.4) | 22.8 (10-61) | NS | 22 (10-62.4) | 22.2 (10-60) | NS |
| Platelets, ×109/L, median (range) | 100 (21-323) | 124 (6-982) | NS | 176 (19-535) | 111 (6-982) | NS | 151 (19-535) | 112 (6-982) | NS |
| Hemoglobin, g/dL, median (range) | 10.6 (7.9-14.2) | 11.1 (4.9-8.5) | NS | 10.8 (8-16.1) | 11.1 (4.9-8.5) | NS | 10.8 (8-16) | 11.1 (4.9-8.5) | NS |
| Blasts BM, % median (range) | 6 (0-19) | 4 (0-19) | NS | 4 (0-15) | 5 (0-19) | NS | 5.5 (0-19) | 4 (0-19) | NS |
| Cytogenetic alterations | 3 (25) | 20 (19.4) | NS | 2 (8.3) | 21 (23.1) | NS | 5 (13.9) | 18 (22.2) | NS |
| Cytogenetic risk | .1 | NS | .1 | ||||||
| Low | 9 (75) | 85 (83.4) | 22 (91.7) | 72 (80) | 31 (86.1) | 65 (81.3) | |||
| Intermediate | 0 | 9 (8.8) | 0 | 9 (10) | 0 | 9 (11.2) | |||
| High | 3 (25) | 8 (7.8) | 2 (8.3) | 9 (10) | 5 (13.9) | 6 (7.5) | |||
| Therapy-related | 1 (10) | 4 (3.8) | NS | 2 (8) | 3 (3.3) | NS | 3 (8.6) | 2 (2.4) | NS |
| ICC/WHO 2022 classification | NS | NS | NS | ||||||
| MD-CMML | 9 (75) | 74 (65.5) | 19 (73.1) | 64 (64.6) | 28 (73.7) | 56 (62.9) | |||
| MP-CMML | 3 (25) | 39 (34.5) | 7 (26.9) | 35 (35.4) | 10 (26.3) | 33 (37.1) | |||
| ICC/WHO 2022 classifications | NS | NS | NS | ||||||
| CMML-1 | 9 (75) | 81 (72.3) | 20 (76.9) | 70 (71.4) | 29 (76.3) | 62 (70.5) | |||
| CMML-2 | 3 (25) | 31 (27.7) | 6 (23.1) | 28 (28.6) | 9 (23.7) | 26 (29.5) | |||
| CPSS | NS | NS | NS | ||||||
| Low | 5 (41.7) | 36 (35) | 12 (50) | 29 (31.9) | 17 (47.2) | 24 (29.6) | |||
| Intermediate-1 | 2 (16.7) | 31 (30) | 6 (25) | 27 (29.7) | 8 (22.2) | 26 (32.1) | |||
| Intermediate-2 | 4 (33.3) | 29 (28.2) | 5 (20.8) | 28 (30.8) | 9 (25) | 25 (30.9) | |||
| High | 1 (8.3) | 7 (6.8) | 1 (4.2) | 7 (7.7) | 2 (5.6) | 6 (7.4) | |||
| Dichotomized CPSS | NS | NS | NS | ||||||
| Low + intermediate-1 | 7 (58.3) | 67 (65) | 18 (75) | 56 (61.5) | 25 (69.4) | 50 (61.7) | |||
| Intermediate-2 + high | 5 (41.7) | 36 (35) | 6 (25) | 35 (38.5) | 11 (30.6) | 31 (38.3) | |||
| CPSS-Mol | NS | NS | NS | ||||||
| Low | 0 | 23 (24.5) | 6 (27.3) | 17 (20.5) | 6 (18.2) | 17 (23.6) | |||
| Intermediate-1 | 4 (36.4) | 23 (24.5) | 7 (31.8) | 20 (24.1) | 11 (33.3) | 16 (22.2) | |||
| Intermediate-2 | 4 (36.4) | 28 (29.8) | 6 (27.3) | 26 (31.3) | 10 (30.3) | 22 (30.6) | |||
| High | 3 (27.2) | 20 (21.2) | 3 (13.6) | 20 (24.1) | 6 (18.2) | 17 (23.6) | |||
| Dichotomized CPSS-Mol | NS | NS | NS | ||||||
| Low + intermediate-1 | 4 (36.4) | 46 (48.9) | 13 (59.1) | 37 (44.6) | 17 (51.5) | 33 (45.8) | |||
| Intermediate-2 + high | 7 (63.6) | 48 (51.1) | 9 (40.9) | 46 (55.4) | 16 (48.5) | 39 (54.2) | |||
| Transfusion dependence | 4 (36.4) | 31 (27.7) | NS | 5 (20) | 30 (30.6) | NS | 9 (25) | 28 (31.5) | NS |
| Patients receiving modifying treatment | 4 (33.3) | 48 (42.5) | NS | 9 (34.6) | 43 (43.4) | NS | 13 (34.2) | 40 (44.9) | NS |
| Patients treated with HMA | 2 (16.7) | 41 (36.3) | NS | 6 (23.1) | 37 (37.4) | NS | 8 (21.1) | 36 (40.4) | .04 |
| Patients treated with chemotherapy | 2 (16.7) | 16 (14.2) | NS | 3 (11.5) | 15 (15.2) | NS | 5 (13.2) | 13 (14.6) | NS |
| Time to treatment, median (range) | 3.1 (2.6-4) | 2.1 (0.1-111.7) | NS | 1.4 (0.3-57.4) | 2.6 (0.1-111.7) | NS | 2.8 (0.3-57.4) | 2.1 (0.1-111.7) | NS |
| Allogeneic transplant | 3 (25) | 20 (17.7) | NS | 4 (15.4) | 19 (19.2) | NS | 7 (18.4) | 17 (19.1) | NS |
| OS, median (95% CI) | 28.7 (0.1-63) | 35.8 (16.8-54.7) | NS | 78.2 (13.6-143) | 28.7 (18-39.5) | NS | 66 (7.3-123.8) | 28.7 (17-40.3) | NS |
| CIP to AML at 2 y, % (95% CI) | 17.6 (2.4-44.6) | 16.6 (10.3-24.2) | NS | 13.4 (3.2-30.9) | 17.9 (10.9-26.3) | NS | 15.3 (5.4-29.9) | 17 (10-25.6) | NS |
| Characteristics . | mutIDH1 (n = 12), n (%) . | wtIDH1 (n = 113), n (%) . | P value . | mutIDH2 (n = 26), n (%) . | wtIDH2 (n = 99), n (%) . | P value . | mutIDH (n = 38), n (%) . | wtIDH (n = 89), n (%) . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| Age, y, median (range) | 74.5 (53-92) | 71 (27.8-95) | NS | 72 (47-87) | 71 (28-95) | NS | 73 (47-92) | 70 (28-95) | NS |
| Sex (man/woman) | 9/3 (75/25) | 85/28 (75.2/24.8) | NS | 22/4 (84.6/15.4) | 72/27 (72.7/27.3) | NS | 31/7 (81.6/18.4) | 65/24 (73/27) | NS |
| Leukocytes, ×109/L, median (range) | 4.9 (3.3-27.6) | 8.3 (2.4-93.7) | NS | 7.2 (3.1-54.3) | 8.3 (2.4-94) | NS | 7.1 (3.1-54) | 9.1 (2.4-94) | NS |
| Neutrophils, median (range) | 1.97 (0.5-14.8) | 3.9 (0.4-41) | NS | 3.4 (0.4-40.3) | 3.9 (0.4-41) | NS | 3.3 (0.4-40.3) | 4.2 (0.4-41) | NS |
| Monocytes, median (range) | 1 (0.7-8.5) | 1.8 (0.5-33.7) | NS | 1.6 (0.5-12.2) | 1.8 (0.5-33.8) | NS | 1.4 (0.5-12.2) | 1.9 (0.5-33.7) | NS |
| % monocytes, median (range) | 23.5 (10.6-60.9) | 21.2 (10-62.4) | NS | 20 (10-62.4) | 22.8 (10-61) | NS | 22 (10-62.4) | 22.2 (10-60) | NS |
| Platelets, ×109/L, median (range) | 100 (21-323) | 124 (6-982) | NS | 176 (19-535) | 111 (6-982) | NS | 151 (19-535) | 112 (6-982) | NS |
| Hemoglobin, g/dL, median (range) | 10.6 (7.9-14.2) | 11.1 (4.9-8.5) | NS | 10.8 (8-16.1) | 11.1 (4.9-8.5) | NS | 10.8 (8-16) | 11.1 (4.9-8.5) | NS |
| Blasts BM, % median (range) | 6 (0-19) | 4 (0-19) | NS | 4 (0-15) | 5 (0-19) | NS | 5.5 (0-19) | 4 (0-19) | NS |
| Cytogenetic alterations | 3 (25) | 20 (19.4) | NS | 2 (8.3) | 21 (23.1) | NS | 5 (13.9) | 18 (22.2) | NS |
| Cytogenetic risk | .1 | NS | .1 | ||||||
| Low | 9 (75) | 85 (83.4) | 22 (91.7) | 72 (80) | 31 (86.1) | 65 (81.3) | |||
| Intermediate | 0 | 9 (8.8) | 0 | 9 (10) | 0 | 9 (11.2) | |||
| High | 3 (25) | 8 (7.8) | 2 (8.3) | 9 (10) | 5 (13.9) | 6 (7.5) | |||
| Therapy-related | 1 (10) | 4 (3.8) | NS | 2 (8) | 3 (3.3) | NS | 3 (8.6) | 2 (2.4) | NS |
| ICC/WHO 2022 classification | NS | NS | NS | ||||||
| MD-CMML | 9 (75) | 74 (65.5) | 19 (73.1) | 64 (64.6) | 28 (73.7) | 56 (62.9) | |||
| MP-CMML | 3 (25) | 39 (34.5) | 7 (26.9) | 35 (35.4) | 10 (26.3) | 33 (37.1) | |||
| ICC/WHO 2022 classifications | NS | NS | NS | ||||||
| CMML-1 | 9 (75) | 81 (72.3) | 20 (76.9) | 70 (71.4) | 29 (76.3) | 62 (70.5) | |||
| CMML-2 | 3 (25) | 31 (27.7) | 6 (23.1) | 28 (28.6) | 9 (23.7) | 26 (29.5) | |||
| CPSS | NS | NS | NS | ||||||
| Low | 5 (41.7) | 36 (35) | 12 (50) | 29 (31.9) | 17 (47.2) | 24 (29.6) | |||
| Intermediate-1 | 2 (16.7) | 31 (30) | 6 (25) | 27 (29.7) | 8 (22.2) | 26 (32.1) | |||
| Intermediate-2 | 4 (33.3) | 29 (28.2) | 5 (20.8) | 28 (30.8) | 9 (25) | 25 (30.9) | |||
| High | 1 (8.3) | 7 (6.8) | 1 (4.2) | 7 (7.7) | 2 (5.6) | 6 (7.4) | |||
| Dichotomized CPSS | NS | NS | NS | ||||||
| Low + intermediate-1 | 7 (58.3) | 67 (65) | 18 (75) | 56 (61.5) | 25 (69.4) | 50 (61.7) | |||
| Intermediate-2 + high | 5 (41.7) | 36 (35) | 6 (25) | 35 (38.5) | 11 (30.6) | 31 (38.3) | |||
| CPSS-Mol | NS | NS | NS | ||||||
| Low | 0 | 23 (24.5) | 6 (27.3) | 17 (20.5) | 6 (18.2) | 17 (23.6) | |||
| Intermediate-1 | 4 (36.4) | 23 (24.5) | 7 (31.8) | 20 (24.1) | 11 (33.3) | 16 (22.2) | |||
| Intermediate-2 | 4 (36.4) | 28 (29.8) | 6 (27.3) | 26 (31.3) | 10 (30.3) | 22 (30.6) | |||
| High | 3 (27.2) | 20 (21.2) | 3 (13.6) | 20 (24.1) | 6 (18.2) | 17 (23.6) | |||
| Dichotomized CPSS-Mol | NS | NS | NS | ||||||
| Low + intermediate-1 | 4 (36.4) | 46 (48.9) | 13 (59.1) | 37 (44.6) | 17 (51.5) | 33 (45.8) | |||
| Intermediate-2 + high | 7 (63.6) | 48 (51.1) | 9 (40.9) | 46 (55.4) | 16 (48.5) | 39 (54.2) | |||
| Transfusion dependence | 4 (36.4) | 31 (27.7) | NS | 5 (20) | 30 (30.6) | NS | 9 (25) | 28 (31.5) | NS |
| Patients receiving modifying treatment | 4 (33.3) | 48 (42.5) | NS | 9 (34.6) | 43 (43.4) | NS | 13 (34.2) | 40 (44.9) | NS |
| Patients treated with HMA | 2 (16.7) | 41 (36.3) | NS | 6 (23.1) | 37 (37.4) | NS | 8 (21.1) | 36 (40.4) | .04 |
| Patients treated with chemotherapy | 2 (16.7) | 16 (14.2) | NS | 3 (11.5) | 15 (15.2) | NS | 5 (13.2) | 13 (14.6) | NS |
| Time to treatment, median (range) | 3.1 (2.6-4) | 2.1 (0.1-111.7) | NS | 1.4 (0.3-57.4) | 2.6 (0.1-111.7) | NS | 2.8 (0.3-57.4) | 2.1 (0.1-111.7) | NS |
| Allogeneic transplant | 3 (25) | 20 (17.7) | NS | 4 (15.4) | 19 (19.2) | NS | 7 (18.4) | 17 (19.1) | NS |
| OS, median (95% CI) | 28.7 (0.1-63) | 35.8 (16.8-54.7) | NS | 78.2 (13.6-143) | 28.7 (18-39.5) | NS | 66 (7.3-123.8) | 28.7 (17-40.3) | NS |
| CIP to AML at 2 y, % (95% CI) | 17.6 (2.4-44.6) | 16.6 (10.3-24.2) | NS | 13.4 (3.2-30.9) | 17.9 (10.9-26.3) | NS | 15.3 (5.4-29.9) | 17 (10-25.6) | NS |
HMA, hypomethylating agents; ICC, International Consensus Classification; CMML, Chronic Myelomonocytic Leukemia; MD, myelodysplastic; BM, bone marrow; mut, mutated; NS, Not Significant; WHO, World Health Organization; wt, wild-type.